fromNature
2 days agoIndividualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC - Nature
DNA repair deficiency, intrinsic genomic instability and an immunogenic tumour microenvironment make TNBC an interesting candidate for individualized vaccination with somatic cancer mutations that can act as neoantigens2,3. We developed an individualized neoantigen RNA vaccine approach that uses next generation sequencing (NGS) for mutation calling and predicts potentially T cell immunity-inducing neoantigens. This approach is being studied in patients with melanoma and pancreatic and other solid cancers4,5,6,7 (Extended Data Fig. 1a).
Cancer





